Serendipitous Collaboration Leads to Potential Therapy for Liver Cancer
The old adage that says two heads are better than one certainly seems true for Mitchell Ho, Ph.D., a senior investigator in the Center for Cancer Research, and Xiaolin Wu, Ph.D., a principal scientist in the Genomics Technology Laboratory, a CCR Core at the Frederick National Laboratory. Together, these two scientists are using next-generation genomics technology to develop, in an animal model, a chimeric antigen receptor T-cell therapy that might help patients with hepatocellular carcinoma, the most common type of liver cancer.